

# Vanna Chiarion Sileni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2008230/publications.pdf>

Version: 2024-02-01

233  
papers

47,867  
citations

11651

70  
h-index

1755

212  
g-index

238  
all docs

238  
docs citations

238  
times ranked

34376  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	27.0	6,773
2	Nivolumab in Previously Untreated Melanoma without BRAF Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	27.0	4,795
3	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	27.0	3,589
4	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2012, 380, 358-365.	13.7	2,691
5	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546.	27.0	2,484
6	Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. <i>New England Journal of Medicine</i> , 2015, 372, 30-39.	27.0	2,240
7	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	27.0	1,752
8	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	27.0	1,572
9	Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1813-1823.	27.0	1,192
10	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 444-451.	13.7	1,175
11	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 1845-1855.	27.0	1,140
12	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC Tj ETQq0 0 0 rgBT /Overlock 10 Tf	16.7	1,093
13	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1480-1492.	10.7	1,089
14	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636.	27.0	909
15	Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 603-615.	10.7	751
16	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 863-873.	10.7	561
17	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. <i>Annals of Oncology</i> , 2017, 28, 1631-1639.	1.2	549
18	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1315-1327.	10.7	469

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. <i>Annals of Oncology</i> , 2010, 21, 1712-1717.	1.2	468
20	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	1.6	446
21	Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1191-1196.	1.6	445
22	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 611-622.	10.7	428
23	Phase III Trial of Initial Chemotherapy in Stage III or IV Head and Neck Cancers: a Study by the Gruppo di Studio sui Tumori della Testa e del Collo. <i>Journal of the National Cancer Institute</i> , 1994, 86, 265-272.	6.3	395
24	Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 3807-3814.	1.6	364
25	Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma. <i>Cancer</i> , 2001, 91, 2165-2174.	4.1	362
26	Adjuvant nivolumab versus ipilimumab in resected stage IIIB and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1465-1477.	10.7	330
27	Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	7.1	295
28	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. <i>Clinical Cancer Research</i> , 2017, 23, 1929-1936.	7.0	290
29	IL4 Myeloid-Derived Suppressor Cell Expansion in Cancer Patients. <i>Journal of Immunology</i> , 2009, 182, 6562-6568.	0.8	287
30	Bleomycin-Based Electrochemotherapy: Clinical Outcome from a Single Institution's Experience with 52 Patients. <i>Annals of Surgical Oncology</i> , 2009, 16, 191-199.	1.5	256
31	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020, 383, 1139-1148.	27.0	256
32	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. <i>Lancet Oncology</i> , The, 2014, 15, 436-444.	10.7	242
33	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2022, 399, 1718-1729.	13.7	236
34	Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600 Mutant Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3441-3449.	1.6	226
35	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	10.7	224
36	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 1389-1398.	10.7	206

#	ARTICLE	IF	CITATIONS
37	VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.. Journal of Clinical Oncology, 1998, 16, 2796-2802.	1.6	204
38	Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, 2413-2420.	1.6	188
39	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncology, The, 2018, 19, 510-520.	10.7	183
40	Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma. Journal of Clinical Oncology, 2013, 31, 1211-1218.	1.6	182
41	Randomized Phase III Trial of Neoadjuvant Chemotherapy in Head and Neck Cancer: 10-Year Follow-Up. Journal of the National Cancer Institute, 2004, 96, 1714-1717.	6.3	167
42	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. European Journal of Cancer, 2017, 82, 45-55.	2.8	160
43	Clinical experience with ipilimumab 3Âmg/kg: real-world efficacy and safety data from an expanded access programme cohort. Journal of Translational Medicine, 2014, 12, 116.	4.4	149
44	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. European Journal of Cancer, 2014, 50, 121-127.	2.8	149
45	Systemic treatments for metastatic cutaneous melanoma. The Cochrane Library, 2020, 2020, CD011123.	2.8	136
46	Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. Journal of Translational Medicine, 2018, 16, 94.	4.4	132
47	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. European Journal of Cancer, 2019, 119, 1-10.	2.8	132
48	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Annals of Oncology, 2020, 31, 1435-1448.	1.2	132
49	Results of esophagectomy for esophageal cancer in elderly patients: Age has little influence on outcome and survival. Journal of Thoracic and Cardiovascular Surgery, 2007, 133, 1186-1192.	0.8	131
50	Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Annals of Oncology, 2013, 24, 2911-2915.	1.2	119
51	Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma. Journal of Clinical Oncology, 2020, 38, 3937-3946.	1.6	119
52	Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunology, Immunotherapy, 2012, 61, 41-48.	4.2	118
53	Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial. Journal of Clinical Oncology, 2002, 20, 1600-1607.	1.6	111
54	Interferon alpha for the adjuvant treatment of cutaneous melanoma. The Cochrane Library, 2015, 2015, CD008955.	2.8	110

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. <i>Journal of Neuro-Oncology</i> , 2014, 118, 109-116.	2.9	103
56	Trends in Management and Prognosis for Esophageal Cancer Surgery. <i>Archives of Surgery</i> , 2009, 144, 247.	2.2	102
57	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 30.	8.6	97
58	Surgery and radiotherapy in the treatment of cutaneous melanoma. <i>Annals of Oncology</i> , 2009, 20, vi22-vi29.	1.2	96
59	Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 358-372.	10.7	94
60	A gene expression signature associated with survival in metastatic melanoma. <i>Journal of Translational Medicine</i> , 2006, 4, 50.	4.4	93
61	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 393-403.	10.7	91
62	Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. <i>Cancer Investigation</i> , 2014, 32, 144-149.	1.3	90
63	Phase II trial of interferon- $\gamma$ 2a plus psolarene with ultraviolet light A in patients with cutaneous T-cell lymphoma. <i>Cancer</i> , 2002, 95, 569-575.	4.1	89
64	Electrochemotherapy for disseminated superficial metastases from malignant melanoma. <i>British Journal of Surgery</i> , 2012, 99, 821-830.	0.3	89
65	Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 1600-1607.	1.6	80
66	Complete Clinical Response After Neoadjuvant Chemoradiotherapy for Squamous Cell Cancer of the Thoracic Oesophagus: Is Surgery Always Necessary?. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 1375-1381.	1.7	77
67	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017, 82, 80-91.	2.8	76
68	Small molecules and targeted therapies in distant metastatic disease. <i>Annals of Oncology</i> , 2009, 20, vi35-vi40.	1.2	75
69	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. <i>European Journal of Cancer</i> , 2019, 119, 97-106.	2.8	75
70	Effects of Neoadjuvant Therapy on Perioperative Morbidity in Elderly Patients Undergoing Esophagectomy for Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2007, 14, 3243-3250.	1.5	74
71	Extramedullary plasmacytoma: Clinical behaviour and response to treatment. <i>Annals of Oncology</i> , 1992, 3, 51-57.	1.2	73
72	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	2.8	71

#	ARTICLE	IF	CITATIONS
73	Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. <i>Melanoma Research</i> , 2001, 11, 189-196.	1.2	70
74	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1449-1461.	1.2	69
75	An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 9013-9013.	1.6	68
76	Interval Between Neoadjuvant Chemoradiotherapy and Surgery for Squamous Cell Carcinoma of the Thoracic Esophagus. <i>Annals of Surgery</i> , 2010, 252, 788-796.	4.2	66
77	First-Line Chemotherapy Improves the Resection Rate and Long-Term Survival of Locally Advanced (T4,) Tj ETQq1 1 0,784314 rgBT /Over	4.2	62
78	Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class Iâ€“Modified Peptides. <i>Clinical Cancer Research</i> , 2012, 18, 6485-6496.	7.0	61
79	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 119, 168-178.	2.8	61
80	Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. <i>Lung Cancer</i> , 2004, 43, 83-91.	2.0	58
81	Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. <i>European Journal of Cancer</i> , 2003, 39, 1577-1585.	2.8	56
82	Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. <i>International Journal of Cancer</i> , 2004, 111, 741-745.	5.1	53
83	Treatment of Chemotherapy-Induced Oral Mucositis with Light-Emitting Diode. <i>Photomedicine and Laser Surgery</i> , 2006, 24, 207-213.	2.0	53
84	Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens. <i>British Journal of Cancer</i> , 2011, 104, 1816-1821.	6.4	53
85	Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. <i>British Journal of Cancer</i> , 2014, 110, 1721-1726.	6.4	53
86	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9502-9502.	1.6	52
87	Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. <i>Oncolmmunology</i> , 2016, 5, e1249559.	4.6	51
88	The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. , 2019, 7, 308.		51
89	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 701-710.	10.7	50
90	Treatments of AIDS-related Kaposi's sarcoma. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 53, 253-265.	4.4	48

#	ARTICLE	IF	CITATIONS
91	Primary Mediastinal Large B-Cell Lymphoma: Results of Intensive Chemotherapy Regimens (MACOP-B/VACOP-B) Plus Involved Field Radiotherapy on 53 Patients. A Single Institution Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 823-829.	0.8	48
92	Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 54, 34-42.	7.7	46
93	Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. <i>Annals of Oncology</i> , 2014, 25, 1428-1436.	1.2	45
94	Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2015, 51, 2086-2094.	2.8	45
95	Expression of defined genes identified by pretreatment tumor profiling: Association with clinical responses to the GSK Mage-A3 immunotherapeutic in metastatic melanoma patients (EORTC Tj ETQq1 1 0.784314rgBT /Overlock 10		
96	Large and Dissimilar Repertoire of Melan-A/MART-1-Specific CTL in Metastatic Lesions and Blood of a Melanoma Patient. <i>Journal of Immunology</i> , 2002, 169, 4017-4024.	0.8	42
97	A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. <i>British Journal of Cancer</i> , 2011, 104, 427-432.	6.4	42
98	Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 264-273.e2.	1.2	41
99	COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF <sup>V600E/K</sup> mutation-positive cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 9011-9011.	1.6	40
100	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
101	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	10.7	37
102	Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. <i>British Journal of Cancer</i> , 2007, 96, 432-438.	6.4	35
103	Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 4737-4745.	7.0	35
104	A retrospective analysis of 141 patients with liver metastases from uveal melanoma. <i>Melanoma Research</i> , 2015, 25, 164-168.	1.2	34
105	Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067). <i>Cancer Research</i> , 2017, 77, CT075-CT075.	0.9	34
106	A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1992, 3, 833-837.	1.2	33
107	Development and External Validation of a Prognostic Nomogram for Metastatic Uveal Melanoma. <i>PLoS ONE</i> , 2015, 10, e0120181.	2.5	33
108	Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 897-908.	4.2	31

#	ARTICLE	IF	CITATIONS
109	Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. <i>European Journal of Cancer</i> , 2017, 79, 176-184.	2.8	31
110	Treatment of multiple myeloma with M-2 protocol and without maintenance therapy. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1983, 19, 1345-1351.	0.7	29
111	Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib. <i>Radiology and Oncology</i> , 2015, 49, 71-74.	1.7	28
112	Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm. <i>Cancer</i> , 1990, 65, 2631-2634.	4.1	27
113	Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 30, 221-225.	2.3	27
114	Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. <i>Melanoma Research</i> , 2015, 25, 75-79.	1.2	27
115	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 121, 144-153.	2.8	27
116	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021, 124, 574-580.	6.4	27
117	The cost of unresectable stage III or stage IV melanoma in Italy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 91.	8.6	25
118	Esophageal Cancer Clinical Presentation. <i>Annals of Surgery</i> , 2018, 267, 99-104.	4.2	25
119	Discrepant alterations in main candidate genes among multiple primary melanomas. <i>Journal of Translational Medicine</i> , 2014, 12, 117.	4.4	24
120	Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical Guidelines. <i>Acta Dermato-Venereologica</i> , 2018, 98, 218-224.	1.3	24
121	Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study. <i>BMC Cancer</i> , 2019, 19, 772.	2.6	24
122	Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach. <i>Journal of Translational Medicine</i> , 2019, 17, 289.	4.4	24
123	Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 82.	8.6	23
124	PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus. <i>Cancer Medicine</i> , 2019, 8, 6036-6048.	2.8	23
125	Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 9504-9504.	1.6	23
126	Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI "Mel.A.") [ISRCTN75125874]. <i>BMC Cancer</i> , 2006, 6, 44.	2.6	22



#	ARTICLE	IF	CITATIONS
127	Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1111-1119.	2.3	22
128	LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno) Tj ETQq0,0,0 rgBT (Overlock 1	1.2	22
129	Cisplatin, bleomycin and methotrexate in the treatment of advanced oesophageal cancer. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1984, 20, 743-747.	0.7	21
130	Surgical Treatment of Melanoma: A Survey of Italian Hospitals. <i>Dermatology</i> , 2013, 226, 28-31.	2.1	21
131	<i>BRAF</i> Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1332-1340.	4.1	21
132	Squamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity. <i>Cancer Science</i> , 2019, 110, 1552-1563.	3.9	21
133	Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study. <i>ESMO Open</i> , 2021, 6, 100064.	4.5	21
134	No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. <i>Cancers</i> , 2021, 13, 475.	3.7	20
135	Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 51, 171-189.	4.4	19
136	Prognostic impact of regression in patients with primary cutaneous melanoma >1mm in thickness. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 99-105.e5.	1.2	19
137	The immune cell landscape of metastatic uveal melanoma correlates with overall survival. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 154.	8.6	19
138	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2021, 158, 156-168.	2.8	19
139	Recombinant alpha-Interferon and vinblastine in metastatic renal cell carcinoma: Efficacy of low doses. <i>Journal of Surgical Oncology</i> , 1988, 4, 184-190.	1.4	18
140	Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. feasibility, toxicity and long-term results of a phase II study. <i>European Journal of Cancer</i> , 1996, 32, 2064-2069.	2.8	18
141	Melanoma Task Force (META) Project in Italy: Methodology. <i>Dermatology</i> , 2013, 226, 1-2.	2.1	18
142	TNF-Based Isolated Limb Perfusion Followed by Consolidation Biotherapy with Systemic Low-dose Interferon Alpha 2b in Patients with In-transit Melanoma Metastases: A Pilot Trial. <i>Annals of Surgical Oncology</i> , 2008, 15, 1218-1223.	1.5	17
143	Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. <i>Journal of Chemotherapy</i> , 2014, 26, 193-201.	1.5	17
144	Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients. <i>Cancers</i> , 2018, 10, 350.	3.7	17

#	ARTICLE	IF	CITATIONS
145	Second and third responses to the same induction regimen in relapsing patients with multiple myeloma. <i>Cancer</i> , 1991, 68, 975-980.	4.1	16
146	Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. <i>Melanoma Research</i> , 2004, 14, 295-299.	1.2	16
147	Neoadjuvant treatment with dabrafenib of unresectable localizations from occult melanoma. <i>Melanoma Research</i> , 2014, 24, 413-414.	1.2	16
148	A germline predictive signature of response to platinum chemotherapy in esophageal cancer. <i>Translational Research</i> , 2016, 171, 29-37.e1.	5.0	16
149	Late relapses in Hodgkin's disease: Outcome of patients relapsing more than twelve months after primary chemotherapy. <i>Annals of Oncology</i> , 1993, 4, 657-662.	1.2	15
150	Functional impairment of p16INK4A due to CDKN2A p.Gly23Asp missense mutation. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2009, 671, 26-32.	1.0	14
151	Positron emission tomography/computed tomography and esophageal cancer in the clinical practice: How does it affect the prognosis?. <i>Journal of Cancer Research and Therapeutics</i> , 2012, 8, 619.	0.9	14
152	Time to diagnosis in esophageal cancer: a cohort study. <i>Acta Oncologica</i> , 2018, 57, 1179-1184.	1.8	14
153	Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma. <i>Scientifica</i> , 2018, 2018, 1-7.	1.7	14
154	An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>European Journal of Cancer</i> , 2019, 107, 175-185.	2.8	13
155	Stanford V Regimen plus Consolidative Radiotherapy Is an Effective Therapeutic Program for Bulky or Advanced-Stage Hodgkin's Disease. <i>Acta Haematologica</i> , 2004, 112, 141-147.	1.4	12
156	Contribution of susceptibility gene variants to melanoma risk in families from the Veneto region of Italy. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 728-730.	3.3	12
157	Paraneoplastic cerebellar degeneration with anti-Yo antibodies associated with metastatic uveal melanoma. <i>Journal of the Neurological Sciences</i> , 2013, 335, 210-212.	0.6	12
158	Systemic treatments for metastatic cutaneous melanoma. <i>The Cochrane Library</i> , 2014, , .	2.8	12
159	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
160	Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. <i>Journal of Translational Medicine</i> , 2022, 20, 159.	4.4	12
161	Cisplatin plus Vindesine versus Cisplatin plus VP16 versus Doxorubicin plus Cytosin in Non-Small-Cell Carcinoma of the Lung. A Randomized Study. <i>Tumori</i> , 1986, 72, 417-425.	1.1	11
162	Lipid Bound Sialic Acid in Cancer Patients. <i>Tumori</i> , 1985, 71, 127-133.	1.1	10

#	ARTICLE	IF	CITATIONS
163	Secondary Leukemia following Treatment for Hodgkin's Disease. <i>Tumori</i> , 1993, 79, 103-107.	1.1	10
164	Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial. <i>Journal of Translational Medicine</i> , 2003, 1, 13.	4.4	10
165	Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma. <i>Melanoma Research</i> , 2006, 16, 317-323.	1.2	10
166	A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience. <i>European Journal of Dermatology</i> , 2017, 27, 482-486.	0.6	10
167	An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival. <i>Frontiers in Oncology</i> , 2020, 10, 1652.	2.8	10
168	Squamous cell carcinoma antigen (SCCA) is up-regulated during Barrett's carcinogenesis and predicts esophageal adenocarcinoma resistance to neoadjuvant chemotherapy. <i>Oncotarget</i> , 2017, 8, 24372-24379.	1.8	10
169	Follow-Up of Melanoma: A Survey of Italian Hospitals. <i>Dermatology</i> , 2013, 226, 32-38.	2.1	9
170	Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9070-9070.	1.6	9
171	Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9590-9590.	1.6	9
172	Peptichemio in pretreated patients with plasmacell neoplasms. <i>European Journal of Cancer &amp; Clinical Oncology</i> , 1986, 22, 1053-1058.	0.7	8
173	Elderly Ovarian Cancer: Treatment with Mitoxantrone+Carboplatin. <i>Gynecologic Oncology</i> , 2001, 80, 221-226.	1.4	8
174	Overdose of Vinblastine in place of Vinorelbine during IGEV chemotherapy. <i>Immunopharmacology and Immunotoxicology</i> , 2012, 34, 879-880.	2.4	8
175	A Therapeutic and Diagnostic Multidisciplinary Pathway for Merkel Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 529.	2.8	8
176	Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East. <i>International Journal of Cancer</i> , 2021, 149, 1926-1934.	5.1	8
177	Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600 mutant unresectable or metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9507-9507.	1.6	8
178	Genetic Features of Metachronous Esophageal Cancer Developed in Hodgkin's Lymphoma or Breast Cancer Long-Term Survivors: An Exploratory Study. <i>PLoS ONE</i> , 2015, 10, e0117070.	2.5	8
179	Reversible, PET-positive, Generalized Lymphadenopathy and Splenomegaly During High-dose Interferon- $\alpha$ -2b Adjuvant Therapy for Melanoma. <i>Journal of Immunotherapy</i> , 2008, 31, 675-678.	2.4	7
180	10760 Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238. <i>Annals of Oncology</i> , 2020, 31, S731-S732.	1.2	7

#	ARTICLE	IF	CITATIONS
181	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). <i>European Journal of Cancer</i> , 2021, 152, 116-128.	2.8	7
182	Epirubicin, methotrexate and bleomycin in the management of recurrent squamous cell head and neck cancer. A GSTTC randomised phase II study. <i>European Journal of Cancer</i> , 1993, 29, 704-708.	2.8	6
183	A Pilot Study of Concomitant Radiation and Chemotherapy in Patients with Locally Advanced Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1993, 16, 264-267.	1.3	6
184	Primary Subcutaneous B-cell Lymphoma: Case Report and Literature Review. <i>Acta Dermato-Venereologica</i> , 2008, 88, 151-154.	1.3	6
185	A Case of Squamous Cell Carcinoma of the Scalp After Several Synthetic Hair Grafts. <i>Aesthetic Plastic Surgery</i> , 2012, 36, 649-652.	0.9	6
186	Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. <i>Future Oncology</i> , 2015, 11, 1355-1362.	2.4	6
187	Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study. <i>Journal of Chemotherapy</i> , 2017, 29, 245-251.	1.5	6
188	Effectiveness of dabrafenib in the treatment of patients with BRAF V600 mutated metastatic melanoma in a Named Patient Program. <i>Melanoma Research</i> , 2019, 29, 527-532.	1.2	6
189	Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 787-792.	0.9	6
190	Merkel Cell Carcinoma: Evaluation of the Clinico-Pathological Characteristics, Treatment Strategies and Prognostic Factors in a Monocentric Retrospective Series (n=143). <i>Frontiers in Oncology</i> , 2021, 11, 737842.	2.8	6
191	Anetoderma in cutaneous marginal-zone B-cell lymphoma. <i>Clinical and Experimental Dermatology</i> , 2009, 34, e945-e948.	1.3	5
192	9307 Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed Phase II trials. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 578.	2.2	5
193	Management of Small and Intermediate Congenital Nevi: A Nationwide Survey in Italy. <i>Dermatology</i> , 2013, 226, 7-12.	2.1	5
194	18F-fluorodeoxyglucose PET/computed tomography and risk stratification after neoadjuvant treatment in esophageal cancer patients. <i>Nuclear Medicine Communications</i> , 2014, 35, 160-168.	1.1	5
195	CASE STUDY ON AN IPIILIMUMAB COST-CONTAINMENT STRATEGY IN AN ITALIAN HOSPITAL. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 199-205.	0.5	5
196	1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial. <i>Annals of Oncology</i> , 2020, 31, S734.	1.2	5
197	Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. <i>Journal of Translational Medicine</i> , 2021, 19, 70.	4.4	5
198	Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). <i>Targeted Oncology</i> , 2021, 16, 789-799.	3.6	5

#	ARTICLE	IF	CITATIONS
199	Leucovorin calcium enhancement of mucositis after continuous infusion fluorouracil and short infusion cisplatin.. Journal of Clinical Oncology, 1989, 7, 680-681.	1.6	4
200	Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer. British Journal of Cancer, 2006, 94, 1550-1552.	6.4	4
201	Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon- $\beta$ . Melanoma Research, 2012, 22, 284-285.	1.2	4
202	Diagnostic and Therapeutic Approaches in Italian Hospitals: Adjuvant and Metastatic Therapy in Melanoma. Dermatology, 2013, 226, 22-27.	2.1	4
203	12th National Congress of the Italian Association of Nuclear Medicine and Molecular Imaging (AIMN) Rimini (Italy), April 16-19, 2015. Clinical and Translational Imaging, 2015, 3, 1-144.	2.1	4
204	Genetic risk of subsequent esophageal cancer in lymphoma and breast cancer long-term survival patients: a pilot study. Pharmacogenomics Journal, 2016, 16, 266-271.	2.0	4
205	Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells. Melanoma Research, 2019, 29, 89-94.	1.2	4
206	Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study. Frontiers in Oncology, 2021, 11, 627527.	2.8	4
207	Serum Copper Level in Non-Hodgkin's Lymphomas. Tumori, 1982, 68, 57-62.	1.1	3
208	Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease. Annals of Oncology, 1995, 6, 173-179.	1.2	3
209	9315 Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy. European Journal of Cancer, Supplement, 2009, 7, 581.	2.2	3
210	Cis-Dichlorodiammineplatinum (II), VP 16-213, and Prednisone (Dvp Regimen) in the Treatment of Pretreated Advanced Malignant Lymphomas. Tumori, 1982, 68, 515-518.	1.1	2
211	Urinary Hydroxyproline in Multiple Myeloma: Correlation with Clinical Stages and Bone Disease. Tumori, 1984, 70, 249-253.	1.1	2
212	Vindesine in Plasma Cell Tumors. Tumori, 1985, 71, 533-536.	1.1	2
213	Radiotherapy Alone in the Treatment of Clinical Stage I-IIA, Nonbulky, Hodgkin's Disease. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 149-152.	1.3	2
214	Impact of Mole Mapping in the Italian Health System. Dermatology, 2013, 226, 13-17.	2.1	2
215	Diagnostic Services for Melanoma in Italy. Dermatology, 2013, 226, 3-6.	2.1	2
216	Clinical electrochemotherapy for advanced superficial melanoma. , 2014, , 35-53.		2

#	ARTICLE	IF	CITATIONS
217	Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma. <i>Annals of Oncology</i> , 2017, 28, v442.	1.2	2
218	Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. <i>Annals of Oncology</i> , 2018, 29, viii445.	1.2	2
219	Cost-effectiveness of a melanoma screening programme using whole disease modelling. <i>Journal of Medical Screening</i> , 2020, 27, 157-167.	2.3	2
220	A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC). <i>Journal of Clinical Oncology</i> , 2009, 27, 4546-4546.	1.6	2
221	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 440.	1.1	1
222	Deflazacort and Fluoximesterone in Advanced, Pretreated Breast Cancer. <i>Tumori</i> , 1992, 78, 266-269.	1.1	1
223	Surgical Management of Suspicious Melanocytic Lesions in Italy. <i>Dermatology</i> , 2013, 226, 18-21.	2.1	1
224	Reply to E. Hindi and K.R. Hess. <i>Journal of Clinical Oncology</i> , 2019, 37, 1356-1358.	1.6	1
225	Cholecystectomy during esophagectomy is safe but unnecessary. <i>Acta Chirurgica Belgica</i> , 2020, 120, 35-41.	0.4	1
226	Efficacy and Safety of Ipilimumab in Patients with Pretreated, Ocular Melanoma: Experience from Italian Clinics Participating in the European Expanded Access Programme (EAP). <i>Annals of Oncology</i> , 2012, 23, ix369-ix370.	1.2	1
227	Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma. <i>Cancer</i> , 2001, 91, 2165-2174.	4.1	1
228	6565 The role of PET-TC in predicting the pCR in locally-advanced esophageal cancer (LAEC) after a preoperative CT-RT treatment: data from B152 trial. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 380.	2.2	0
229	Complete and lasting healing of bone melanoma metastasis after hyperthermic limb perfusion. <i>Melanoma Research</i> , 2009, 19, 193-194.	1.2	0
230	Safety and Efficacy of Ipilimumab 10 Mg/Kg Among Patients with Advanced Melanoma from Italy Enrolled in a European Compassionate Use Program. <i>Annals of Oncology</i> , 2012, 23, ix373-ix374.	1.2	0
231	1100P Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanoma. <i>Annals of Oncology</i> , 2020, 31, S743-S744.	1.2	0
232	Identification of host variants associated with overall survival of esophageal cancer patients receiving platinum-based therapy. <i>Pharmacogenomics</i> , 2020, 21, 393-402.	1.3	0
233	Altitude Effect on Cutaneous Melanoma Epidemiology in the Veneto Region (Northern Italy): A Pilot Study. <i>Life</i> , 2022, 12, 745.	2.4	0